

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


## **Single Technology Appraisal**

# Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409

## **Final Stakeholder List**

| Provisional Consultees  | Provisional Commentators (no right to submit or appeal)  |
|---|--|
| Company   | General  |
| argenx (efgartigimod with recombinant human hyaluronidase PH20) | <ul> <li>All Wales Therapeutics and Toxicology<br/>Centre</li> <li>Allied Health Professionals Federation</li> </ul> |
| Patient/carer groups  Brain and Spine Foundation                | Board of Community Health Councils in<br>Wales   |
| Brain Charity   |  |
| Guillain-Barré and Associated                                   | <ul><li>British National Formulary</li><li>Care Quality Commission</li></ul>   |
| Inflammatory Neuropathies (GAIN)                                | Department of Health - Northern Ireland  |
| Neurological Alliance   | Healthcare Improvement Scotland  |
| <ul> <li>South Asian Health Foundation</li> </ul>               | Medicines and Healthcare products  |
| Specialised Healthcare Alliance                                 | Regulatory Agency  |
|   | <ul> <li>National Association of Primary Care</li> </ul>   |
| Healthcare professional groups                                  | National Pharmacy Association  |
| <ul> <li>Association of British Neurologists</li> </ul>         | Neurological Alliance of Scotland  |
| British Geriatrics Society                                      | NHS Confederation  |
| British Neuropathological Society                               | NHS Wales Joint Commissioning  |
| British Peripheral Nerve Society                                | Committee  |
| Chartered Society of Physiotherapy                              | <ul> <li>Scottish Medicines Consortium</li> </ul>  |
| <ul> <li>National Neurosciences Advisory</li> </ul>             | Wales Neurological Alliance  |
| Group   | Welsh Government   |
| Physiotherapy Pain Association                                  |  |
| Primary Care and Community                                      | Possible comparator companies  |
| Neurology Society   | Aspen (azathioprine)   |
| Royal College of General Practitioners                          | Bio Products Laboratory (human   |
| Royal College of Nursing  | immunoglobulin)  |
| Royal College of Pathologists  Payal College of Physicians      | CSL Behring UK (human     ingress a glabstilin)  |
| Royal College of Physicians                                     | immunoglobulin)  |
| Royal Pharmaceutical Society     Royal Society of Madicine      | Dexcel Pharma (ciclosporin)     Crifola III (human immunaglahulin)   |
| Royal Society of Medicine     LCL Institute of Neurology        | Grifols UK (human immunoglobulin)     LER Biophermacouticals (human  |
| UCL Institute of Neurology     UK Clinical Pharmacy Association | <ul> <li>LFB Biopharmaceuticals (human immunoglobulin)</li> </ul>  |
| UK Clinical Pharmacy Association                                | Morningside healthcare (ciclosporin)   |
| <u>Others</u>   | <ul> <li>Mylan (azathioprine, ciclosporin)</li> </ul>  |
| Department of Health and Social Care                            | <ul> <li>Nova Laboratories (azathioprine)</li> </ul>   |
| NHS England   | Novartis (ciclosporin)   |
|   | Octapharma (human immunoglobulin)  |

Final stakeholder list for the evaluation of efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409 Issue date: August 2025



| Provisional Consultees | Provisional Commentators (no right to submit or appeal)   |
|------------------------|---|
|                        | <ul> <li>Roche (mycophenolate mofetil)</li> <li>Rosemont Pharmaceuticals (mycophenolate mofetil)</li> <li>Santen (ciclosporin)</li> <li>Strides Pharma (azathioprine)</li> <li>Sun Pharmaceuticals (ciclosporin)</li> <li>Takeda UK (human immunoglobulin)</li> <li>Teva Pharma (mycophenolate mofetil)</li> <li>Tillomed Laboratories (azathioprine, mycophenolate mofetil)</li> </ul> |
|                        | <ul> <li>Relevant research groups</li> <li>Brain Research UK</li> <li>Genomics England</li> <li>Institute of Neurology</li> <li>MRC Clinical Trials Unit</li> <li>National Hospital for Neurology and Neurosurgery</li> <li>National Institute for Health Research</li> </ul>   |
|                        | <ul> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>   |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.





The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.